Jefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS)

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best strong buy growth stocks to buy now. On August 21, Jefferies analyst Tycho Peterson reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS) and set a price target of $80.00.

Exact Sciences Corporation (NASDAQ:EXAS) reported its fiscal Q2 2025 earnings on August 6, announcing a record total revenue of $811 million for the quarter, up 16% on a reported and core revenue basis.

The company raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively, and also announced a multi-year productivity plan targeting $150 million in annual savings by 2026.

Exact Sciences Corporation (NASDAQ:EXAS) is a diagnostics and screening company that focuses on the early detection and prevention of particular types of cancer. It offers Cologuard, a non-invasive screening test for the early detection of colorectal cancer, pre-cancer, and Oncotype DX.

While we acknowledge the potential of EXAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.